nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2015-2-2-77-83nodgo-105Research ArticleПРОБЛЕМЫ ПРАКТИЧЕСКОЙ ГЕМАТОЛОГИИ-ОНКОЛОГИИPROBLEMS OF PRACTICAL HEMATOLOGY/ONCOLOGYВНУТРИВЕННЫЕ ИММУНОГЛОБУЛИНЫ: ПРИМЕНЕНИЕ СОВРЕМЕННЫХ ФИЗИОЛОГИЧНЫХ РАСТВОРОВ СПОСОБНО УЛУЧШИТЬ РЕЗУЛЬТАТЫ ТЕРАПИИINTRAVENOUS IMMUNOGLOBULINS: APPLICATION OF MODERN PHYSIOLOGICAL SOLUTION IS ABLE TO IMPROVE RESULTS OF THE THERAPYКиргизовК. И.KirgizovK. I.nodgo@yandex.ruСкоробогатоваЕ. В.SkorobogatovaE. V.ФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России; Россия, 117198, Москва, ул. Саморы Машела, 1 ФГБУ «Российская детская клиническая больница» Минздрава России; Россия, 117997, Москва, Ленинский просп., 117РоссияFederal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia; 1 Samory Mashela St., Moscow, 117198, Russia; Russian Children,s Clinical Hospital, Ministry of Health of Russia; 117 Leninskiy Prosp., Moscow, 117997, RussiaRussian Federation2ФГБУ «Российская детская клиническая больница» Минздрава России; Россия, 117997, Москва, Ленинский просп., 117Россия2Russian Children,s Clinical Hospital, Ministry of Health of Russia; 117 Leninskiy Prosp., Moscow, 117997, RussiaRussian Federation201529052015227783Copyright © Киргизов К.И., Скоробогатова Е.В., 20152015Киргизов К.И., Скоробогатова Е.В.Kirgizov K.I., Skorobogatova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/105

Продолжая серию публикаций о применении внутривенных иммуноглобулинов (ВВИГ) как одного из базисных препаратов в терапии иммунологических, гематологических и онкологических заболеваний, в данном материале мы сфокусировались на безопасности современных препаратов ВВИГ. В статье представлены основные требования к растворам ВВИГ и меры улучшения данных препаратов для предотвращения побочных действий. В материале дана обновленная статистика по применению 10 % ВВИГ в федеральном центре.

While continuing the series of publications on the application of intravenous immunoglobulins (IVIG), as one of basic substances in the therapy of immunologic, hematologic and oncologic diseases we have focused on the safety of modern IVIG substances. The article comprises main requirements to IVIG solutions, as well as measures for the improvement of such substances in order to prevent adverse effects. The material comprises the updated statistics on the application of 10 % IVIG in the federal center.

внутривенные иммуноглобулиныдетигематология-онкологиятрансплантация гемопоэтических стволовых клетокбезопасностьочисткаintravenous immunoglobulinschildrenhematology-oncologyhematopoietic stem cell transplantationsafetypurificationReferencesFehr J., Hofmann V., Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982;306(21): 1254–8.Fehr J., Hofmann V., Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982;306(21): 1254–8.Sumer T., Abumelha A., al-Mulhim I., al-Fadil M. et al. Treatment of fever and neutropenia with antibiotics versus antibiotics plus intravenous immunoglobulin in childhood leukemia. Eur J Pediatr 1989;148(5):401–2.Sumer T., Abumelha A., al-Mulhim I., al-Fadil M. et al. Treatment of fever and neutropenia with antibiotics versus antibiotics plus intravenous immunoglobulin in childhood leukemia. Eur J Pediatr 1989;148(5):401–2.Sullivan K. M., Kopecky K. J., Jocom J. et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990;323(11):705–12.Sullivan K. M., Kopecky K. J., Jocom J. et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990;323(11):705–12.Киргизов К. И., Шаманская Т. В., Пристанскова Е. А. и др. Применение внутривенных иммуноглобулинов в детской гематологии-онкологии и транс-плантации гемопоэтических стволовых клеток: свойства и показания – опыт федеральных центров. Российский журнал детской гематологии и онкологии 2014;3:44–50. [Kirgizov K. I., Shamanskaya T. V., Pristanskova E. A. et al. Use of intravenous immunoglobulins in pediatric hematology/oncology and hematopoietic stem cell transplantation: Properties and indications (federal centers, experience). Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Children Hematology and Oncology 2014;3:44–50. (In Russ.)].Киргизов К. И., Шаманская Т. В., Пристанскова Е. А. и др. Применение внутривенных иммуноглобулинов в детской гематологии-онкологии и транс-плантации гемопоэтических стволовых клеток: свойства и показания – опыт федеральных центров. Российский журнал детской гематологии и онкологии 2014;3:44–50. [Kirgizov K. I., Shamanskaya T. V., Pristanskova E. A. et al. Use of intravenous immunoglobulins in pediatric hematology/oncology and hematopoietic stem cell transplantation: Properties and indications (federal centers, experience). Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Children Hematology and Oncology 2014;3:44–50. (In Russ.)].Durandy A., Kaveri S. V., Kuijpers T. W. et al. Intravenous immunoglobulins – understanding properties and mechanisms. Clin Exp Immunol 2009;158 Suppl 1: 2–13.Durandy A., Kaveri S. V., Kuijpers T. W. et al. Intravenous immunoglobulins – understanding properties and mechanisms. Clin Exp Immunol 2009;158 Suppl 1: 2–13.Gelfand E. W. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006;6:592–9.Gelfand E. W. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006;6:592–9.Черешнев В. А., Шмагель К. В. Иммунология. М., 2014. [Chereshnev V. A., Shmagel K. V. Immunology. M., 2014. (In Russ.)].Черешнев В. А., Шмагель К. В. Иммунология. М., 2014. [Chereshnev V. A., Shmagel K. V. Immunology. M., 2014. (In Russ.)].de Beukelaar J. W., Sillevis Smitt P. A. Managing paraneoplastic neurological disorders. Oncologist 2006;11(3):292–305.de Beukelaar J. W., Sillevis Smitt P. A. Managing paraneoplastic neurological disorders. Oncologist 2006;11(3):292–305.Soler-Palacín P., Gasó-Gago I., Fernández-Polo A. et al. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies. J Clin Immunol 2014;34(8):1015–7.Soler-Palacín P., Gasó-Gago I., Fernández-Polo A. et al. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies. J Clin Immunol 2014;34(8):1015–7.Feasby T., Banwell B., Benstead T. et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007;21(2 Suppl 1):S57–107.Feasby T., Banwell B., Benstead T. et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007;21(2 Suppl 1):S57–107.Масчан А. А., Ковалева Л. Г., Румянцев А. Г., Савченко В. Г. Современные методы диагностики и лечения первичной иммунной тромбоцитопении (по итогам совещания совета экспертов). Санкт-Петербург, май 2010 г. Вопросы гематологии, онкологии и иммунопатологии в педиатрии 2010;9(4):5–14. [Maschan A. A., Kovaleva L. G., Rumyantsev A. G., Savchenko V. G. Modern methods for diagnosis and treatment of primary immune thrombocytopenia (summing up the Expert Council meeting). St. Petersburg, May 2010. Voprosy gematologii, onkologii i immunopatologii v pediatrii = Questions of Hematology, Oncology and Immunopathology in Pediatrics 2010;9(4):5–14. (In Russ.)].Масчан А. А., Ковалева Л. Г., Румянцев А. Г., Савченко В. Г. Современные методы диагностики и лечения первичной иммунной тромбоцитопении (по итогам совещания совета экспертов). Санкт-Петербург, май 2010 г. Вопросы гематологии, онкологии и иммунопатологии в педиатрии 2010;9(4):5–14. [Maschan A. A., Kovaleva L. G., Rumyantsev A. G., Savchenko V. G. Modern methods for diagnosis and treatment of primary immune thrombocytopenia (summing up the Expert Council meeting). St. Petersburg, May 2010. Voprosy gematologii, onkologii i immunopatologii v pediatrii = Questions of Hematology, Oncology and Immunopathology in Pediatrics 2010;9(4):5–14. (In Russ.)].Raanani P., Gafter-Gvili A., Paul M. et al. Immunoglobulin prophylaxisRaanani P., Gafter-Gvili A., Paul M. et al. Immunoglobulin prophylaxisin hematopoetic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 2009;27(5):770–81.in hematopoetic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 2009;27(5):770–81.Guérin V., Yakouben K., Lescoeur B. et al Prolonged agammaglobulinemia despite unaltered B-cell lymphopoiesis after peritransplant-rituximab administration in a child. Transplantation 2008;86(9):1322–3.Guérin V., Yakouben K., Lescoeur B. et al Prolonged agammaglobulinemia despite unaltered B-cell lymphopoiesis after peritransplant-rituximab administration in a child. Transplantation 2008;86(9):1322–3.Hicks L. K., Woods A., Buckstein R. et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009;43(9):701–8.Hicks L. K., Woods A., Buckstein R. et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009;43(9):701–8.Renal insufficiency and failure associated with immune globulin intravenous therapy – United States, 1985–1998. MMWR Morb Mortal Wkly Rep 1999;48(24):518–21.Renal insufficiency and failure associated with immune globulin intravenous therapy – United States, 1985–1998. MMWR Morb Mortal Wkly Rep 1999;48(24):518–21.Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol 2013;38(4):275–84.Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol 2013;38(4):275–84.Funk M. B., Gross N., Gross S. et al. Thromboembolic events associatedFunk M. B., Gross N., Gross S. et al. Thromboembolic events associatedwith immunoglobulin treatment. Vox Sang 2013;105(1):54–64.with immunoglobulin treatment. Vox Sang 2013;105(1):54–64.Darbà J., Restovic G., Kaskens L., de Agustín T. Direct medical costs of liquid intravenous immunoglobulins in children, adolescents, and adults in Spain. J Clin Pharmacol 2012;52(4):566–75.Darbà J., Restovic G., Kaskens L., de Agustín T. Direct medical costs of liquid intravenous immunoglobulins in children, adolescents, and adults in Spain. J Clin Pharmacol 2012;52(4):566–75.Bolli R., Woodtli K., Bärtschi M. et al. L-proline reduces IgG dimer contentBolli R., Woodtli K., Bärtschi M. et al. L-proline reduces IgG dimer contentand enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals 2010;38(1):150–7.and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals 2010;38(1):150–7.Daw Z., Padmore R., Neurath D. et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008;48(8):1598–601.Daw Z., Padmore R., Neurath D. et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008;48(8):1598–601.Divan H., Menis M., Sridhar G. et al. Occurrence of hemolytic reactions (HRs) on the same day as immune globulin (IG) product administrations during 2008–2012 (Poster presented at 29th ICPE congress, 2013).Divan H., Menis M., Sridhar G. et al. Occurrence of hemolytic reactions (HRs) on the same day as immune globulin (IG) product administrations during 2008–2012 (Poster presented at 29th ICPE congress, 2013).Siani B., Willimann K., Wymann S. et al. Isoagglutinin reduction in human immunoglobulin products by donor screening. Biol Ther 2014;4:15–26.Siani B., Willimann K., Wymann S. et al. Isoagglutinin reduction in human immunoglobulin products by donor screening. Biol Ther 2014;4:15–26.Hubsch A., EI Menyawi I., Siani B. et al. Isoagglutinin depletion in human immunoglobulin products: donor screening or a specific immunoaffininty chromatography step. Poster presented at the 16th Biennal Meeting of the European Society for Immunodeficiencies (ESID) 29.10–01.11.2014, Prague, Czech Republic.Hubsch A., EI Menyawi I., Siani B. et al. Isoagglutinin depletion in human immunoglobulin products: donor screening or a specific immunoaffininty chromatography step. Poster presented at the 16th Biennal Meeting of the European Society for Immunodeficiencies (ESID) 29.10–01.11.2014, Prague, Czech Republic.

The authors declare that there are no conflicts of interest present.